- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Blood Biomarker Offers Earlier Detection of Pancreatic Cancer
A new blood biomarker demonstrates its ability to detect pancreatic cancer earlier, which can lead to better treatment and outcomes, according to a study published in Science Translational Medicine.
A new blood biomarker demonstrates its ability to detect pancreatic cancer earlier, which can lead to better treatment and outcomes, according to a study published in Science Translational Medicine.
In the United States over 53,000 people are diagnosed with pancreatic cancer per year, but most are not diagnosed until an advanced stage when tumors can no longer be surgically removed. Ken Zaret, PhD, of the University of Pennsylvania School of Medicine, and Gloria Petersen, PhD, from the Mayo Clinic, led the team that found a pair of biomarkers that can be used to detect pancreatic cancer sooner.
"Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer," stated Zaret in a press release.
The researchers predict that the presence of the biomarker will be tested through blood drawn from pancreatic cancer patients and those at a high risk of developing the disease.
"Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer," said Robert Vonderheide, MD, DPhil, director of the the University of Pennsylvania’s Abramson Cancer Center, in the press statement. "Having a biomarker test for this disease could dramatically alter the outlook for these patients."
The biomarker was developed by reprogramming late-stage human cancer cells to a stem cell state, which forces the reprogrammed cells to an early cancerous stage and reveals blood biomarkers of the disease. Plasma thrombospondin-2 (THBS2) was found to be the best biomarker candidate because when screened against 746 cancer and control plasma samples, the blood levels of THBS2 combined with the later-stage biomarker CA19-9 were reliable at identifying pancreatic cancer.
"Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer," Zaret concluded. "Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method."
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More
